|Reactivity||Human, Mouse, Rat|
|Calculated MW||H=22;M=22;Rat=22 KDa|
|Antigen Region||123-150 aa|
|Other Names||VSNL1; VISL1; Visinin-like protein 1; Hippocalcin-like protein 3|
|Target/Specificity||This VILIP1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 123-150 amino acids from the C-terminal region of human VILIP1.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||VILIP1 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Regulates (in vitro) the inhibition of rhodopsin phosphorylation in a calcium-dependent manner.|
|Tissue Location||Brain and retina. Neuron-specific in the central and peripheral nervous system. Increased in the cerebrospinal fluid of Alzheimer disease patients (at protein level).|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The visinin and visinin-like peptides represent a family of calcium-binding proteins that are highly expressed in the retina. Visinin has been shown to be a cone cell-specific protein with a molecular weight of 24 kDa. Several members of the visinin family of genes have been isolated and characterized from different species. These peptides are believed to be involved in the processes of phototransduction. The recoverin gene (RCV1) is believed to be involved in the pathophysiology of retinopathy in cancer patients.
Braunewell, K.H., et al., Neuropharmacology 44(6):707-715 (2003). Lin, L., et al., J. Biol. Chem. 277(44):41872-41878 (2002). Spilker, C., et al., J. Neurosci. 22(17):7331-7339 (2002). Bernstein, H.G., et al., Neuroreport 13(4):393-396 (2002). Lin, L., et al., Biochem. Biophys. Res. Commun. 296(4):827-832 (2002).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.